HGEN News and Press, Humanigen Inc. From 12/28/20

The USPTO has issued a patent to Humanigen (HGEN) for the use of lenzilumab in prevention or treatment of cytokine storm, neurotoxicity in patients undergoing chimeric antigen receptor T (CAR-T) cell therapy and inhibit or reduce incidence or severity of CAR-T-related toxicities. Th...

Humanigen, Inc . (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced the Uni...

Gainers: Mereo BioPharma (MREO) +91%, Cyclo Therapeutics (CYTH) +44%, Petros Pharmaceuticals (PTPI) +29%, CNS Pharmaceuticals (CNSP) +17%, Humanigen (HGEN) +17%.Losers: Mesoblast (MESO) -34%, Virios Therapeutics (VIRI) -30%, BioCardia (BCDA) -...

Humanigen (HGEN) has completed enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme ((GBM)).Results from the study, being conducted in Australia, are expected in H1 2021. The primary goal of the Phase 1 study is to evaluate sa...

Humanigen, Inc . (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Co...

Humanigen, Inc . (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases, today announced completing enrollment in its Phase 1 ...

vTv Therapeutics VTVT +128% as MacAndrews & Forbes buys 625K shares.Sonoma Pharmaceuticals SNOA +122% on Crown Laboratories partnership.FAT Brands FAT +60% on plan to merge with controlling shareholder Fog Cutter Capital.Lexicon Pharmaceuticals LXRX +38%...

New Humanigen entity in Australia creates focused opportunity for partnering, regional clinical trials and market access Structure allows for attractive financial incentives supported by the Australian government Humanigen, Inc . (NASDAQ: HGEN) (&...

Humanigen (HGEN): Q3 GAAP EPS of -$0.71 misses by $0.16.As of September 30, 2020, the Company had cash and cash equivalents of $91.4M. We expect our expenses to continue to increase significantly in the remaining three months of 2020 as a result of securing additional manufacturing capac...

-Underwritten Public Offering and Nasdaq Listing Completed in September 2020 -Positive Phase 3 Interim Analysis Reported with an Estimated 37 percent More Recoveries Observed in the Lenzilumab Arm Versus Current Standard of Care Humanigen, Inc. , (HGEN)...